EVAX
Evaxion AS
NASDAQ · Healthcare · Biotechnology · DK
$2.97
+0.34%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$3.12
From 52W high−55.20%
Volume27622.00
Market cap$26.79M
P/E (TTM)—
P/S (TTM)3.6x
Div yield—
Key dataNov 4, 2026
Open
$3.12
From 52W high
−55.20%
Volume
27622.00
Market cap
$26.79M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.0x
P/E (TTM)
—
RSI (14)
49.6
MomentumView details →
1D Return
+0.34%
YTD Return
−33.96%
SummaryUpdated Jun 1, 2026
Evaxion Biotech A/S (NASDAQ:EVAX) is a Danish clinical-stage biotechnology company founded in 2008 and headquartered in Hørsholm, Denmark. The company went public on NASDAQ in February 2021. Evaxion specializes in developing artificial intelligence-powered immunotherapies targeting cancers, bacterial diseases, and viral infections. The company has evolved from a traditional biotech firm into an AI-driven immunotherapy platform company, leveraging proprietary machine learning algorithms to identify and develop novel vaccine candidates across multiple therapeutic areas.
Similar companies
Latest newsMore news →
Evaxion A/S received the 2026 International Evaxion A/S Award for AI-Immunology as the best digital health solution.6d agoEvaxion A/S announced new three-year immune and clinical outcome data for its personalized cancer vaccine EVX-01 in patients with advanced melanoma, reporting 89% vaccine target precision and sustained T-cell and clinical responses.13d ago